Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor, Adult × tislelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 52 Carcinoma, Hepatocellular 37 Stomach Neoplasms 29 Colorectal Neoplasms 28 Esophageal Squamous Cell Carcinoma 21 Squamous Cell Carcinoma of Head and Neck 15 Neoplasm Metastasis 11 Advanced Solid Tumor 11 Head and Neck Neoplasms 10 Esophageal Neoplasms 10 Triple Negative Breast Neoplasms 9 Small Cell Lung Carcinoma 9 Rectal Neoplasms 8 Nasopharyngeal Carcinoma 8 Lung Neoplasms 8 Cholangiocarcinoma 8 Recurrence 7 Neoplasms 7 Melanoma 7 Colonic Neoplasms 7 Uterine Cervical Neoplasms 5 Solid Tumor 5 Pancreatic Neoplasms 5 Lymphoma 5 Carcinoma, Transitional Cell 5 Advanced Solid Tumors 5 Urinary Bladder Neoplasms 4 Lymphoma, Extranodal NK-T-Cell 4 Locally Advanced Rectal Cancer 4 Hodgkin Disease 4

Interventions

pembrolizumab 5 Radiotherapy 3 Proton Therapy 3 Interleukin-2 3 Cyclophosphamide 3 spartalizumab 2 fludarabine 2 Paclitaxel 2 Ipilimumab 2 Immune Checkpoint Inhibitors 2 Cetuximab 2 Carboplatin 2 Blood Specimen Collection 2 toripalimab 1 tislelizumab 1 sotorasib 1 peposertib 1 pazopanib 1 patritumab deruxtecan 1 palbociclib 1 niraparib 1 neotil 1 necitumumab 1 leronlimab 1 lenvatinib 1 atezolizumab 1 abemaciclib 1 Yoga 1 Watchful Waiting 1 Valganciclovir 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06032845 2025-02-27

CASTLE-11

Fudan University

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon ⚡